ALSO NOTED: Biogen says safety first, efficacy second; Roche chief unconcerned by Tykerb; and much more...

> A top executive for Biogen Idec says developers should place a greater emphasis on safety than effectiveness. Article

> Roche's pharmaceutical chief says he isn't concerned by the prospect of new competition for Herceptin from GSK's Tykerb. Report

> Shares of Avanir were depressed by the news that the FDA will extend its review period for Neurodex by 90 days. Report

> Chutes & Ladders: Transave of Monmouth Junction, NJ Timothy G. Whitten as president and CEO. Release

> Sanofi-Aventis has seen a drop of 25 percent in French drug sales as the result of government cost-cutting efforts in Europe. Report

> EMD Pharmaceuticals has submitted an NDA for Cyanokit to the FDA. Release

And Finally… A new study shows how people's perspectives on vaccinations shift as they adopt different roles in the healthcare system, with actions ranging widely in the switch from patient to medical director. Article